ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
58 |
15K |
1 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
58
|
15K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
vrs37
|
59 |
19K |
3 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
59
|
19K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
vrs37
|
59 |
19K |
1 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
59
|
19K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
58 |
15K |
6 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
58
|
15K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
vrs37
|
59 |
19K |
1 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
59
|
19K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
vrs37
|
59 |
19K |
0 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
59
|
19K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
|
|
vrs37
|
21 |
7.7K |
0 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
21
|
7.7K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
vrs37
|
77 |
25K |
2 |
05/01/24 |
05/01/24 |
ASX - By Stock
|
77
|
25K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
vrs37
|
77 |
25K |
3 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
77
|
25K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
vrs37
|
77 |
25K |
1 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
77
|
25K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
vrs37
|
77 |
25K |
8 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
77
|
25K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix (ASX: DXB) Discussion Thread
|
|
vrs37
|
640 |
215K |
8 |
31/12/23 |
31/12/23 |
ASX - By Stock
|
640
|
215K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix (ASX: DXB) Discussion Thread
|
|
vrs37
|
640 |
215K |
5 |
27/12/23 |
27/12/23 |
ASX - By Stock
|
640
|
215K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First USA site initiated in aGvHD trial
|
|
vrs37
|
31 |
8.3K |
2 |
27/12/23 |
27/12/23 |
ASX - By Stock
|
31
|
8.3K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
65K |
3 |
11/12/23 |
11/12/23 |
ASX - By Stock
|
231
|
65K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
65K |
5 |
09/12/23 |
09/12/23 |
ASX - By Stock
|
231
|
65K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
65K |
3 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
231
|
65K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
65K |
1 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
231
|
65K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
News: ATX Amplia Therapeutics Says Approval From Korean Regulator
|
|
vrs37
|
13 |
4.8K |
3 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
13
|
4.8K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
65K |
4 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
231
|
65K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
65K |
4 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
231
|
65K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
65K |
2 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
231
|
65K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
News: ATX Amplia Therapeutics Says Approval From Korean Regulator
|
|
vrs37
|
13 |
4.8K |
3 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
13
|
4.8K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
65K |
0 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
231
|
65K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
65K |
1 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
231
|
65K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: ACTION3 IND Approved in China
|
|
vrs37
|
231 |
65K |
3 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
231
|
65K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: mRNA Vaccine Enhancer Shows Inflammation Reduction
|
|
vrs37
|
45 |
19K |
1 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
45
|
19K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: AGM Presentation
|
|
vrs37
|
77 |
25K |
8 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
77
|
25K
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Ann: mRNA Vaccine Enhancer Shows Inflammation Reduction
|
|
vrs37
|
45 |
19K |
0 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
45
|
19K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Announces License Agreement for EU, Canada, ANZ
|
|
vrs37
|
423 |
149K |
3 |
20/11/23 |
20/11/23 |
ASX - By Stock
|
423
|
149K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Announces License Agreement for EU, Canada, ANZ
|
|
vrs37
|
423 |
149K |
1 |
18/11/23 |
18/11/23 |
ASX - By Stock
|
423
|
149K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Announces License Agreement for EU, Canada, ANZ
|
|
vrs37
|
423 |
149K |
3 |
17/11/23 |
17/11/23 |
ASX - By Stock
|
423
|
149K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
vrs37
|
26 |
8.3K |
2 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
26
|
8.3K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: AACR Pancreatic Cancer Conference Presentation
|
|
vrs37
|
2 |
1K |
1 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
2
|
1K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma
|
|
vrs37
|
155 |
40K |
4 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
155
|
40K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma
|
|
vrs37
|
155 |
40K |
6 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
155
|
40K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma
|
|
vrs37
|
155 |
40K |
7 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
155
|
40K
|
7
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
vrs37
|
26 |
8.3K |
5 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
26
|
8.3K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
vrs37
|
26 |
8.3K |
7 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
26
|
8.3K
|
7
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
16 |
11K |
3 |
07/11/21 |
07/11/21 |
ASX - By Stock
|
16
|
11K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
16 |
11K |
2 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
16
|
11K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
16 |
11K |
3 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
16
|
11K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Impact of COVID-19 on clinical trials
|
|
vrs37
|
15 |
5.1K |
2 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
15
|
5.1K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Impact of COVID-19 on clinical trials
|
|
vrs37
|
15 |
5.1K |
2 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
15
|
5.1K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
IONIC
|
|
vrs37
|
14 |
4.6K |
1 |
13/09/21 |
13/09/21 |
ASX - By Stock
|
14
|
4.6K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
A message to trolls
|
|
vrs37
|
12 |
3.7K |
6 |
03/09/21 |
03/09/21 |
ASX - By Stock
|
12
|
3.7K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Wonder Drug
|
|
vrs37
|
29 |
7.4K |
6 |
24/08/21 |
24/08/21 |
ASX - By Stock
|
29
|
7.4K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Wonder Drug
|
|
vrs37
|
29 |
7.4K |
5 |
24/08/21 |
24/08/21 |
ASX - By Stock
|
29
|
7.4K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Program to Expand After Positive Phase 1 Results
|
|
vrs37
|
49 |
14K |
2 |
23/08/21 |
23/08/21 |
ASX - By Stock
|
49
|
14K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Program to Expand After Positive Phase 1 Results
|
|
vrs37
|
49 |
14K |
3 |
23/08/21 |
23/08/21 |
ASX - By Stock
|
49
|
14K
|
3
|
|